Aakash Desai· @ADesaiMD · X·· 18 hours agoScore70
Body · original
#ESMO26 Phase 1 Temab-A (c-Met ADC), NSQ NSCLC @abbvie
➡️ EGFR WT (n=48): ORR 50%, mPFS 6.8, mOS 13.8 mo
➡️ EGFRm (n=41): ORR 63%, mPFS 10.9, mOS 16.2 mo
➡️ WT c-Met 3+ ≥10%: mOS 25.2 vs 9.7 mo
Small changes to payload, big impact?
@LungCancerRx @OncoAlert @oncodaily
168 views · 4 likes · 2 reposts · 0 replies
Conference abstracts
1017Pmatched by Developmental therapeutics
Phase 1 first-in-human (FIH) results of YL211, a c-Met targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors
https://esmocongress.esmo.orgNCT06110663NCT06110663matched by - **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
https://esmocongress.esmo.orgSource: Aakash Desai · x.com